Warner Greene, MD, PhD

Headshot of Warner Greene
User Profile Photo

Warner Greene, MD, PhD

User Profile Name
Director, Gladstone Center for HIV Cure Research
Professor, School of Medicine
User Profile Title
User Profile Email

Biography

Warner C. Greene, MD, PhD is Director of the Gladstone Center for HIV Cure Research, Senior Investigator, and Nick and Sue Hellmann Distinguished Professor of Translational Medicine at the Gladstone Institute of Virology and Immunology (GIVI). He is the Founding and Emeritus Director of GIVI. Dr. Greene is also Professor of Medicine, Microbiology and of Immunology at UCSF. Dr. Greene is a member of the Institute of Medicine of the National Academies and a fellow of the American Academy for the Advancement of Science. He also serves as Co-Director of the UCSF-Gladstone Center for AIDS Research, and has served as a Councilor and President of the Association of American Physicians. Dr. Greene earned a bachelor’s degree at Stanford University and an MD/PhD at Washington University School of Medicine. He took his internship and residency training in Medicine at the Massachusetts General Hospital at Harvard. After serving as a Senior Investigator at the National Cancer Institute and a Professor of Medicine and Howard Hughes Investigator at Duke University Medical Center, Dr. Greene accepted his current position as the Founding Director of the Gladstone Institute of Virology and Immunology in 1991. The ongoing research in Dr. Greene’s laboratory focuses on the molecular mechanisms underlying HIV pathogenesis, latency, and transmission. He is the author of more than 380 scientific papers and has been recognized as one of the 100 Most Cited Scientists in the world. In 2007, Dr. Greene expanded his work to include global health in sub-Saharan Africa in his service as president and executive chairman of the Accordia Global Health Foundation. Accordia established the Infectious Diseases Institute at Makerere University in Uganda, which has trained thousands of African health care workers, is caring for 30,000 HIV-infected patients, and has brought health care to nearly 500,000 people living in remote rural regions of Uganda. In 2016, Accordia merged with Africare.
CTSI Profile Bio

Displaying 226 - 250 of 386

  1. Molitor JA, Ballard DW, Greene WC. Kappa B-specific DNA binding proteins are differentially inhibited by enhancer mutations and biological oxidation. New Biol. 1991 Oct; 3(10):987-96.
  2. Smith MR, Greene WC. Type I human T cell leukemia virus tax protein transforms rat fibroblasts through the cyclic adenosine monophosphate response element binding protein/activating transcription factor pathway. J Clin Invest. 1991 Sep; 88(3):1038-42.
  3. Bogerd HP, Huckaby GL, Ahmed YF, Hanly SM, Greene WC. The type I human T-cell leukemia virus (HTLV-I) Rex trans-activator binds directly to the HTLV-I Rex and the type 1 human immunodeficiency virus Rev RNA response elements. Proc Natl Acad Sci U S A. 1991 Jul 01; 88(13):5704-8.
  4. Lee JH, Li YC, Doerre S, Sista P, Ballard DW, Greene WC, Franza BR. A member of the set of kappa B binding proteins, HIVEN86A, is a product of the human c-rel proto-oncogene. Oncogene. 1991 Apr; 6(4):665-7.
  5. Hémar A, Cereghini S, Cornet V, Blank V, Israël A, Greene WC, Dautry-Varsat A. Kappa B binding proteins are constitutively expressed in an IL-2 autocrine human T cell line. J Immunol. 1991 Apr 01; 146(7):2409-16.
  6. Smith MR, Greene WC. Molecular biology of the type I human T-cell leukemia virus (HTLV-I) and adult T-cell leukemia. J Clin Invest. 1991 Mar; 87(3):761-6.
  7. Ahmed YF, Gilmartin GM, Hanly SM, Nevins JR, Greene WC. The HTLV-I Rex response element mediates a novel form of mRNA polyadenylation. Cell. 1991 Feb 22; 64(4):727-37.
  8. Greene WC. The molecular biology of human immunodeficiency virus type 1 infection. N Engl J Med. 1991 Jan 31; 324(5):308-17.
  9. Smith MR, Greene WC. Functional analyses of the type I human T-cell leukemia virus tax gene product. Trans Assoc Am Physicians. 1991; 104:78-91.
  10. Kim JH, Kaufman PA, Hanly SM, Rimsky LT, Greene WC. Rex transregulation of human T-cell leukemia virus type II gene expression. J Virol. 1991 Jan; 65(1):405-14.
  11. Molitor JA, Walker WH, Doerre S, Ballard DW, Greene WC. NF-kappa B: a family of inducible and differentially expressed enhancer-binding proteins in human T cells. Proc Natl Acad Sci U S A. 1990 Dec; 87(24):10028-32.
  12. Ballard DW, Walker WH, Doerre S, Sista P, Molitor JA, Dixon EP, Peffer NJ, Hannink M, Greene WC. The v-rel oncogene encodes a kappa B enhancer binding protein that inhibits NF-kappa B function. Cell. 1990 Nov 16; 63(4):803-14.
  13. Smith MR, Greene WC. Identification of HTLV-I tax trans-activator mutants exhibiting novel transcriptional phenotypes. Genes Dev. 1990 Nov; 4(11):1875-85.
  14. Cullen BR, Greene WC. Functions of the auxiliary gene products of the human immunodeficiency virus type 1. Virology. 1990 Sep; 178(1):1-5.
  15. Rubin LA, Galli F, Greene WC, Nelson DL, Jay G. The molecular basis for the generation of the human soluble interleukin 2 receptor. Cytokine. 1990 Sep; 2(5):330-6.
  16. Kuziel WA, Greene WC. Interleukin-2 and the IL-2 receptor: new insights into structure and function. J Invest Dermatol. 1990 Jun; 94(6 Suppl):27S-32S.
  17. Ahmed YF, Hanly SM, Malim MH, Cullen BR, Greene WC. Structure-function analyses of the HTLV-I Rex and HIV-1 Rev RNA response elements: insights into the mechanism of Rex and Rev action. Genes Dev. 1990 Jun; 4(6):1014-22.
  18. Fung MR, Greene WC. The human interleukin-2 receptor: insights into subunit structure and growth signal transduction. Semin Immunol. 1990 Mar; 2(2):119-28.
  19. Mills GB, May C, McGill M, Fung M, Baker M, Sutherland R, Greene WC. Interleukin 2-induced tyrosine phosphorylation. Interleukin 2 receptor beta is tyrosine phosphorylated. J Biol Chem. 1990 Feb 25; 265(6):3561-7.
  20. Greene WC. Regulation of HIV-1 gene expression. Annu Rev Immunol. 1990; 8:453-75.
  21. Pomerantz JL, Mauxion F, Yoshida M, Greene WC, Sen R. A second sequence element located 3' to the NF-kappa B-binding site regulates IL-2 receptor-alpha gene induction. J Immunol. 1989 Dec 15; 143(12):4275-81.
  22. Hammes SR, Dixon EP, Malim MH, Cullen BR, Greene WC. Nef protein of human immunodeficiency virus type 1: evidence against its role as a transcriptional inhibitor. Proc Natl Acad Sci U S A. 1989 Dec; 86(23):9549-53.
  23. Smith MR, Greene WC. The same 50-kDa cellular protein binds to the negative regulatory elements of the interleukin 2 receptor alpha-chain gene and the human immunodeficiency virus type 1 long terminal repeat. Proc Natl Acad Sci U S A. 1989 Nov; 86(21):8526-30.
  24. Rimsky L, Dodon MD, Dixon EP, Greene WC. Trans-dominant inactivation of HTLV-I and HIV-1 gene expression by mutation of the HTLV-I Rex transactivator. Nature. 1989 Oct 05; 341(6241):453-6.
  25. Ballard DW, Böhnlein E, Hoffman JA, Bogerd HP, Dixon EP, Franza BR, Greene WC. Activation of the interleukin-2 receptor alpha gene: regulatory role for DNA-protein interactions flanking the kappa B enhancer. New Biol. 1989 Oct; 1(1):83-92.